CDKN2A and melanoma: To ascertain if this result could be validated in vivo, we injected YUMM1.7 melanoma cells derived from the B-RafV600E/Pten-/-/Cdkn2A-/- mouse model intradermally into C57BL/6 mice of either 8 weeks of age or >52 weeks of age.